ZYNE - Zynerba Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
13.79
+0.37 (+2.76%)
At close: 4:00PM EDT

14.11 +0.32 (2.32%)
After hours: 7:58PM EDT

Stock chart is not supported by your current browser
Previous Close13.42
Open13.45
Bid14.11 x 900
Ask14.00 x 800
Day's Range13.30 - 13.93
52 Week Range2.75 - 16.47
Volume1,393,745
Avg. Volume2,737,439
Market Cap290.464M
Beta (3Y Monthly)5.45
PE Ratio (TTM)N/A
EPS (TTM)-2.19
Earnings DateAug 9, 2017 - Aug 14, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est21.75
Trade prices are not sourced from all markets
  • Understanding Medical Cannabis vs. Recreational Cannabis Stocks
    Investopedia6 days ago

    Understanding Medical Cannabis vs. Recreational Cannabis Stocks

    Medical marijuana and recreational marijuana are two high growth sectors in the cannabis industry. Learn about how the two differ, and how you can get into the market.

  • Benzinga6 days ago

    MediaJel Acquires Potnt Agency, Adds Merida Capital's Thomas Harrison As Chairman

    The company appointed Thomas Harrison, Senior Operating Partner at Merida Capital Partners, as Chairman of the Board. Before joining the company, Harrison was Chairman Emeritus of Omnicom Group Inc (NYSE: OMC)’s Diversified Agency Services for 17 years, helping DAS became one of the world’s largest holding companies for marketing services companies.

  • Zynerba Pharmaceuticals (ZYNE) Gains As Market Dips: What You Should Know
    Zacks7 days ago

    Zynerba Pharmaceuticals (ZYNE) Gains As Market Dips: What You Should Know

    Zynerba Pharmaceuticals (ZYNE) closed the most recent trading day at $13.52, moving +0.15% from the previous trading session.

  • Zynerba Up on Second Patent for Cannabidiol Candidate in 2019
    Zacks7 days ago

    Zynerba Up on Second Patent for Cannabidiol Candidate in 2019

    Zynerba (ZYNE) gets a new U.S. patent covering methods of treating autism spectrum disorder with cannabidiol, a key compound of its lead pipeline candidate, Zygel.

  • Why Zynerba Pharmaceuticals Stock Is Skyrocketing Today
    Motley Fool8 days ago

    Why Zynerba Pharmaceuticals Stock Is Skyrocketing Today

    A new patent is generating excitement among investors for this clinical-stage biotech stock.

  • Zynerba Stock Soars on Cannabidiol Patent for Autism Spectrum Disorder
    InvestorPlace8 days ago

    Zynerba Stock Soars on Cannabidiol Patent for Autism Spectrum Disorder

    Shares of Zynerba Pharmaceuticals (NASDAQ:ZYNE) are surging Tuesday after the company landed a patent for the treatment of autism spectrum disorder. Specifically, the patent covers treatment using cannabidiol, which will surely add a spark to ZYNE stock.Source: Zynerba PharmaceuticalsThe stock was up 8% in pre-market trading and there's potential for this name to run even further once investors catch wind of it. We're seeing that play out now, with shares up 18% in Tuesday morning trading.With a market capitalization just under $250 million, it's not a well-known player like Biogen (NASDAQ:BIIB) or Celgene (NASDAQ:CELG). In the same light, it's not even a well-known cannabis stock, like Canopy Growth (NYSE:CGC) or Aurora Cannabis (NYSE:ACB).InvestorPlace - Stock Market News, Stock Advice & Trading TipsZynerba was issued U.S. Patent No. 10,314,792, which is titled, "Treatment of Autism Spectrum Disorder with Cannabidiol" and runs through 2038. So if the treatment is successful, ZYNE stock will have the rights to this treatment for almost two decades. The PatentZynerba is building out a portfolio of different treatments based around its potential cannabidiol product Zygel. I say "potential" because there's still a lot of work and progress needed before this becomes a staple in the medicine cabinet, so to say. * 7 Dark Horse Stocks Winning the Race in 2019 The patented treatment "includes claims directed to methods of treating autism spectrum disorder by administering a therapeutically effective amount of synthetic cannabidiol." It was granted during the enrollment period of a Phase 2 BRIGHT study, which is intended to evaluate "the safety, tolerability and efficacy of Zygel for the treatment of children and adolescents with Autism Spectrum Disorder."Will it work? At this stage it's impossible to say, but there is promise. GW Pharmaceuticals (NASDAQ:GWPH) has successfully gained traction -- even here in the U.S. -- with its cannabidiol treatment for epileptic seizures. So if Zynerba can show similar successes with its treatment, it may open the door to other possible treatments in the future using its Zygel product. Trading ZYNE Stock Click to Enlarge The big boost in ZYNE stock comes as little surprise. After all, it's got all the right buzzwords working in its favor, even if the company has good intentions. Wall Street latches to these trends and investors aren't afraid to jump on board if they think there's opportunity. That's even as Phase-2 testing has yet to begin.ZYNE stock chart is one of only a few that could make a double-digit gain look fairly modest. Above you can see how it moved over downtrend resistance (blue line) on Monday. Now it's pushing through $13, as well as the 20-day moving average.Can this thing ignite through $14 and tag its 2019 high near $16.50? Yes, it can. There's no guarantee that it will, but these sort of momentum boosters can give a huge shot in the arm to small-cap stocks.Whether that justifies a move this powerful, ZYNE stock investors certainly have a reason to be excited. But there's a lot of room on the upside before Zynerba stock exhausts itself.On the downside, I want to see $11 to $11.50 hold as support.This marks the 50-day moving average (which is trending higher) as well as the 38.2% retracement. That said, it would be highly discouraging to see ZYNE stock lose all of Tuesday's gains. Bottom Line on ZYNE StockNorth of $13 and the 20-day would be best, but let's see how it trades throughout the day and the rest of this week.Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell is long CELG. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Dark Horse Stocks Winning the Race in 2019 * 6 Chinese Stocks to Sell That Are Suffering From a Digital Ad Slowdown * 4 Technology Stocks Blasting Higher Compare Brokers The post Zynerba Stock Soars on Cannabidiol Patent for Autism Spectrum Disorder appeared first on InvestorPlace.

  • Zynerba Pharmaceuticals Rises Due to Patent News
    Market Realist8 days ago

    Zynerba Pharmaceuticals Rises Due to Patent News

    Zynerba Pharmaceuticals Rises Due to Patent NewsZynerba PharmaceuticalsZynerba Pharmaceuticals (ZYNE) has risen 18.6% as of 10:40 AM EST on June 11. The stock has been among the top-performing stocks this year. The stock has year-to-date gains of

  • Benzinga8 days ago

    Zynerba Advances Cannabidiol Treatment With New Patent Win

    Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE), a company that focuses on treating rare and near-rare neuropsychiatric disorders through cannabinoid therapies, said Tuesday it received a new U.S. patent for one of its cannabis-focused treatments. Zynerba said the U.S. Patent and Trademark Office issued US Patent No. 10,314,792, titled "Treatment of Autism Spectrum Disorder with Cannabidiol." The patent includes claims related to methods of treating autism through the administration of a synthetic cannabidiol. Need more cannabis news?

  • GlobeNewswire8 days ago

    Zynerba Pharmaceuticals Receives New U.S. Patent for Treatment of Autism Spectrum Disorder with Cannabidiol

    Zynerba Pharmaceuticals, Inc. (ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that the U.S. Patent and Trademark Office has issued US Patent No. 10,314,792, titled “Treatment of Autism Spectrum Disorder with Cannabidiol” which includes claims directed to methods of treating autism spectrum disorder by administering a therapeutically effective amount of synthetic cannabidiol. This new patent, which expires in 2038, is part of an expanding intellectual property portfolio covering the Company's cannabidiol (CBD) product candidate, Zygel™ (ZYN002 transdermal CBD gel). This patent follows the previously announced issuance of US Patent No. 10,213,390, titled “Treatment of Fragile X Syndrome with Cannabidiol” which includes claims directed to methods of treating Fragile X Syndrome by administering a therapeutically effective amount of synthetic or purified cannabidiol.

  • Top Marijuana Stocks on the NASDAQ
    Investopedia9 days ago

    Top Marijuana Stocks on the NASDAQ

    The cannabis industry has grown in recent months and years, and many companies in the cannabis and health-related industries have been uplisted to reputable U.S. exchanges. Learn about the marijuana stocks on the Nasdaq.

  • Zynerba Pharmaceuticals: Analysts See More Upside after the Rally
    Market Realist12 days ago

    Zynerba Pharmaceuticals: Analysts See More Upside after the Rally

    Zynerba Pharmaceuticals: Analysts See More Upside after the RallyZynerba PharmaceuticalsSo far, Zynerba Pharmaceuticals (ZYNE) has seen an upwards price action of 265% in 2019. Analysts see more upside in the stock. The mean consensus target price

  • Here's What Last Week's FDA CBD Hearing Really Means for Cannabis Stocks
    Motley Fool15 days ago

    Here's What Last Week's FDA CBD Hearing Really Means for Cannabis Stocks

    The bottom line: a whole lot of uncertainty.

  • Market Exclusive19 days ago

    Zynerba Initiates Phase II INSPIRE Trial Of Zygel

    Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) has announced the launch of the second phase of its INSPIRE trial evaluating the company’s lead candidate Zygel which is a transdermal cannabidiol gel that treats emotional and behavioral symptoms of 22q11.2 deletion symptoms. Topline results for INSPIRE trial expected next year 22q11.2 deletion condition is an inherited pediatric condition whose […]The post Zynerba Initiates Phase II INSPIRE Trial Of Zygel appeared first on Market Exclusive.

  • GlobeNewswire20 days ago

    Zynerba Pharmaceuticals to Present at FDA’s Public Hearing on Scientific Data and Information about Products Containing Cannabis or Cannabis-derived Compounds

    Zynerba Pharmaceuticals, Inc. (ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Ray Mannion, Zynerba’s Vice President of Manufacturing, will provide a formal presentation during the U.S. Food and Drug Administration’s (FDA) Public Hearing on Scientific Data and Information about Products Containing Cannabis or Cannabis-Derived Compounds. Slides from Mr. Mannion’s presentation, entitled ‘Cannabinoid Manufacturing and Product Quality’, are now available on Zynerba’s corporate website at https://zynerba.com/publications/. “The FDA has a well-established history of protecting public health and safety through a variety of essential strategies, including existing regulations and processes that govern the manufacture of pharmaceutical products and establish controls to ensure necessary quality and safety standards are met,” said Armando Anido, Chairman and Chief Executive Officer of Zynerba.

  • GlobeNewswire21 days ago

    Zynerba Pharmaceuticals Announces Initiation of Phase 2 Trial of Zygel™ in 22q11.2 Deletion Syndrome

    Zynerba Pharmaceuticals, Inc. (ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that it has initiated the Phase 2 INSPIRE (Assessing the Impact of Zygel [Transdermal CBD Gel] on Pediatric Behavioral and Emotional Symptoms of 22q11.2 Deletion Syndrome) trial. The INSPIRE trial will assess the safety, tolerability and efficacy of Zygel (ZYN002 CBD gel) for the treatment of behavioral symptoms of 22q11.2 Deletion Syndrome (22q).

  • GlobeNewswire22 days ago

    Zynerba Pharmaceuticals to Present at the Jefferies 2019 Global Healthcare Conference

    Zynerba Pharmaceuticals, Inc. (ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido will present a company overview at the Jefferies 2019 Global Healthcare Conference. A live webcast of the presentation will be accessible on the Investor Relations page of http://www.zynerba.com. Zynerba Pharmaceuticals is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders.

  • 3 ‘Strong Buy’ Cannabis Biotech Stocks To Know Now
    TipRanks22 days ago

    3 ‘Strong Buy’ Cannabis Biotech Stocks To Know Now

    If you are looking to invest in cannabis stocks, you may want to take a closer look at cannabis biotechs in particular. Several cannabis biotech firms are generating significant Street support- and for good reason as you will see below. To pinpoint the most compelling cannabis biotech stocks out there, we used TipRanks' data to pull up relevant biotechs with a 'Strong Buy' Street consensus. That's based on all the ratings received from analysts over the last three months. In fact, all these three stocks actually score 100% Street support- so no hold or sell ratings here. Let's take a closer look now at which 3 stocks make the grade, and why: GW Pharmaceuticals (GWPH – Research Report)British-based biopharma GWPH is one of the more well-known cannabis biotech stocks. Shares have put on a remarkable sprint for the beginning of 2019. Year-to-date we are now looking at gains of 88%. And the company’s recent earnings report indicates that plenty of growth lies ahead. In June 2018, the company’s lead cannabinoid drug Epidiolex received FDA approval for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome. Following DEA re-scheduling, Epidiolex was launched on November 1.So far the launch has proved a remarkable success. For the first quarter, GW reported $33.5MM in Epidiolex revenue during its first full quarter on the market, well ahead of consensus ($15.9MM). But even more importantly, the company also revealed positive trial data for tuberous sclerosis complex (TSC). Specifically, GW announced that Epidiolex's Phase III trial in patients with seizures associated with tuberous sclerosis complex (TSC) met its primary endpoint with a high degree of statistical significance.The primary endpoint was the percent change from baseline in seizure frequency during the treatment period. At baseline, enrolled patients (average age of 14 years old) experienced a median of 57 seizures per month. After 16 weeks of treatment, patients in the 25 mg/kg/day cohort experienced an impressive 48.6% reduction in seizures relative to baseline.“1Q Snapshot \- A Strong Launch and Positive TSC Data Rolled Into a Joint Announcement for a Double Dose of Good News” cheered JP Morgan’s Cory Kasimov following the report. The analyst continued: “We’re not sure how GWPH’s 1Q19 report could have gone much better with Epidiolex doubling consensus in its first full quarter of sales… only to be one-upped by concurrent positive Phase 3 data in TSC.”As a result he believes Epidiolex is on track to come in north of $150M in its first full year, easily exceeding Street expectations. “The bottom line is that estimates need to come up, perhaps meaningfully. Furthermore, with another positive – and clean – phase 3 dataset in hand, there could be upward bias to longer term off label epilepsy sales, which offers a major upside lever in our model” concludes Kasimov. He reiterated his buy rating while ramping up his price target from $180 to $215. Unsurprisingly, he wasn’t the only analyst singing GWPH’s praises. “Based on Epidiolex's trajectory and the positive TSC data today we are increasing our DCF-based price target from $175 to $200. We continue to think that GW is undervalued” commented Cowen & Co’s Phil Nadeau. At the same time Oppenheimer’s Esther Rajavelu took a step further by upgrading GWPH from Hold to Buy. She also upped her price target from $164 to a Street-high $234 (27% upside). “While we await detailed data that may be shared at a medical conference, we update our probability of approval of the sNDA [supplemental new drug application] for TSC to 87% from 41% (filing expected in 4Q)” she explained. Overall GWPH has a very bullish outlook from the Street, with ten analysts publishing recent buy ratings on the stock. Their average analyst price target stands at $220- indicating upside potential of 20%. View GWPH Price Target & Analyst Ratings Detail Zynerba Pharmaceuticals Inc (ZYNE – Research Report)Zynerba is developing next-generation cannabinoid gels to help treat patients affected by rare neuropsychiatric conditions. The company is generating a significant buzz, with shares exploding over 340% year-to-date! So what’s behind the stock’s meteoric rise?Its lead drug candidate Zygel is a unique permeation-enhanced CBD transdermal gel. By delivering drugs through the skin and directly into the circulatory system, Zygel offers several advantages over oral medication. Most notably, transdermal delivery results in fewer gastrointestinal side effects, and avoidance of first-pass liver metabolism. This potentially enables lower dosage levels of active pharmaceutical ingredients and rapid, reliable absorption. Encouragingly, Zynerba announced earlier this month that the FDA has granted a Fast Track designation on Zygel for the treatment of behavioral problems associated with Fragile X syndrome (FXS). “With this designation, the company gains easier access to the FDA throughout the development process and most importantly, in our view, eligibility for Priority Review, which shortens the review time to six months” explains Ladenburg’s Michael Higgins. He anticipates Zygel’s NDA (new drug application filing) will take place in 1H20, leading to approval in 2H20. And with an eye on the future, Higgins reiterates his buy rating on ZYNE with a $26 price target (97% upside potential). While data since the summer of 2018 has been light, multiple major data readouts are comping up near-term- generating the recent rally in prices. “We continue to believe the stock could still double from its current level, driven by a data-rich 2H’19” the analyst tells investors. Upcoming data readouts include Phase 2 data from BELIEVE 1, evaluating Zygel’s anti-epileptic activity, and data from the FXS pivotal CONNECT-FX trail. “Given the unprecedented, profound and sustained benefits across multiple behavioral problems in the open-label Phase 2 (FAB-C), plus Zygel’s good tolerability, we again expect this trial to be successful” writes Higgins. Plus the catalysts should continue into 1H20 when data is expected for two new indications (autism spectrum disorder (ASD) and 22q11.2 deletion syndrome). Analysts are clearly feeling the heat- this is a stock with five recent back-to-back buy ratings and an average analyst price target of $23 (79% upside potential). View ZYNE Price Target & Analyst Ratings Detail Cara Therapeutics Inc (CARA – Research Report)Cara Therapeutics is a biotech focusing on developing products for better pruritus (i.e. severe itching- one of the most common dermatological complaints) and pain management. Right now, all eyes are squarely set on the imminent US Phase 3 data for IV Korsuva. This is Cara’s novel kappa opioid receptor agonist to treat chronic kidney disease-associated pruritus (CKD-aP) in hemodialysis patients- where there is currently no effective treatment and minimal competitive development.Indeed top-rated Cantor Fitzgerald analyst Charles Duncan has just hosted a call with a key opinion leader (KOL) to discuss the outlook for Korsuva. In this case the KOL is a physician with expertise in chronic kidney disease associated pruritus (CKD-aP), making his insights particularly valuable. Overall, the KOL stated that, in his 25 years as a practicing nephrologist, he has seen little in drug development move the needle in CKD-aP (except the P2 data from KORSUVA), underscoring the need for new medications.“As a result of this recent due diligence, we have enhanced conviction about the P3 study readouts and potential for KORSUVA to usher-in a paradigm shift and a new SoC [standard of care] for this high-burden symptom of disease” Duncan concluded. He expects the data readout to come early June, and is upbeat about the drug's prospects. “We remain confident in positive results based on statistically significant Phase 2b results with much lower powering and shorter treatment duration” the analyst tells investors. Meanwhile, the second global Phase 3, KALM-2, is enrolling and management expects data in “2H19” (i.e. around 4Q). "Assuming KALM-1 is positive, we’ll also be optimistic for KALM-2", says the analyst. He reiterated his buy rating with a $27 price target, writing ‘Now is the time to scratch the itch.’ Given the stock is currently only trading at $18, the price target translates into sizable upside potential of over 50%. Bear in mind shares are already soaring 39% year-to-date. As we can see here, that's on top of six recent buy ratings from the Street:View CARA Price Target & Analyst Ratings Detail Enjoy Research Reports on the Stocks in this Article:Cara Therapeutics Inc (CARA) Research ReportGW Pharmaceuticals (GWPH) Research ReportZynerba Pharmaceuticals Inc (ZYNE) Research Report

  • Is Zynerba Pharmaceuticals (ZYNE) Outperforming Other Medical Stocks This Year?
    Zacks26 days ago

    Is Zynerba Pharmaceuticals (ZYNE) Outperforming Other Medical Stocks This Year?

    Is (ZYNE) Outperforming Other Medical Stocks This Year?

  • UC Davis researcher looks to cannabis compound to treat developmental disorders
    American City Business Journals26 days ago

    UC Davis researcher looks to cannabis compound to treat developmental disorders

    Dr. Randi Hagerman is on the front lines of developing new treatments for kids with autism, Down syndrome and other developmental disorders.

  • Options Traders Expect Huge Moves in Zynerba Pharmaceuticals (ZYNE) Stock
    Zacks27 days ago

    Options Traders Expect Huge Moves in Zynerba Pharmaceuticals (ZYNE) Stock

    Investors need to pay close attention to Zynerba Pharmaceuticals (ZYNE) stock based on the movements in the options market lately.

  • Zynerba Pharmaceuticals, Inc. (ZYNE) Shares March Higher, Can It Continue?
    Zacks29 days ago

    Zynerba Pharmaceuticals, Inc. (ZYNE) Shares March Higher, Can It Continue?

    As of late, it has definitely been a great time to be an investor in Zynerba Pharmaceuticals, Inc. (ZYNE).

  • Can We See Significant Insider Ownership On The Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Share Register?
    Simply Wall St.last month

    Can We See Significant Insider Ownership On The Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Share Register?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...

  • Associated Presslast month

    Zynerba: 1Q Earnings Snapshot

    On a per-share basis, the Devon, Pennsylvania-based company said it had a loss of 47 cents. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...

  • GlobeNewswirelast month

    Zynerba Pharmaceuticals Reports First Quarter 2019 Financial Results and Operational Highlights

    DEVON, Pa., May 08, 2019 -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and.